SG Americas Securities LLC raised its position in shares of Vericel Co. (NASDAQ:VCEL – Get Rating) by 52.3% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 9,974 shares of the biotechnology company’s stock after acquiring an additional 3,424 shares during the period. SG Americas Securities LLC’s holdings in Vericel were worth $251,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Capital Advisory Group Advisory Services LLC acquired a new stake in shares of Vericel in the first quarter valued at approximately $76,000. Summit Creek Advisors LLC increased its holdings in shares of Vericel by 0.4% in the first quarter. Summit Creek Advisors LLC now owns 334,657 shares of the biotechnology company’s stock valued at $12,791,000 after purchasing an additional 1,278 shares in the last quarter. Fort Washington Investment Advisors Inc. OH acquired a new stake in shares of Vericel in the first quarter valued at approximately $9,200,000. Lisanti Capital Growth LLC acquired a new stake in shares of Vericel in the first quarter valued at approximately $5,088,000. Finally, KBC Group NV acquired a new stake in shares of Vericel in the second quarter valued at approximately $110,000.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on VCEL. StockNews.com initiated coverage on shares of Vericel in a report on Wednesday, October 12th. They issued a “sell” rating for the company. Truist Financial cut shares of Vericel from a “buy” rating to a “hold” rating in a research note on Wednesday. Stephens initiated coverage on shares of Vericel in a research note on Thursday, October 13th. They issued an “overweight” rating and a $40.00 price objective on the stock. Finally, BTIG Research cut shares of Vericel from a “buy” rating to a “neutral” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Vericel has an average rating of “Hold” and an average price target of $38.00.
Vericel Stock Down 23.4 %
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
- Get a free copy of the StockNews.com research report on Vericel (VCEL)
- Is Triple-Digit Growth Ahead For Digital Ad Platform Trade Desk?
- EV Maker Lucid Falls On Declining Orders, Rivian Up On Guidance
- DoorDash Outperforms Despite Losses – Is It Time To Buy?
- Goodyear Tire & Rubber Stock is Becoming a Mighty Good Bargain
- Analysts Rate DraftKings a Moderate Buy As Growth Slows
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.